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Abstract
Cell proliferation involves dramatic changes in DNA metabolism and cell division, and control of DNA replication, mitosis,
and cytokinesis have received the greatest attention in the cell cycle field. To catalogue a wider range of cell cycle-regulated
processes, we employed quantitative proteomics of synchronized HeLa cells. We quantified changes in protein abundance
as cells actively progress from G1 to S phase and from S to G2 phase. We also describe a cohort of proteins whose
abundance changes in response to pharmacological inhibition of the proteasome. Our analysis reveals not only the
expected changes in proteins required for DNA replication and mitosis but also cell cycle-associated changes in proteins
required for biological processes not known to be cell-cycle regulated. For example, many pre-mRNA alternative splicing
proteins are down-regulated in S phase. Comparison of this dataset to several other proteomic datasets sheds light on
global mechanisms of cell cycle phase transitions and underscores the importance of both phosphorylation and
ubiquitination in cell cycle changes.
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Introduction
The cell cycle is highly regulated to ensure accurate duplication
and segregation of chromosomes. Perturbations in cell cycle
control can result in genome instability, cell death, and oncogen-
esis [1,2,3,4]. Critical transition points in the cell cycle reflect
‘‘points of no return’’ that are difficult or impossible to reverse. For
example, the G1 to S phase transition, marked by the onset of
DNA replication, is an essentially irreversible step, as is mitosis.
For this reason, the major cell cycle transitions into and out of S
phase and mitosis are under particularly complex and robust
control. The mechanisms that govern such cell cycle transitions
include changes in protein abundance that are driven by
combinations of regulated gene expression and protein stability
control (reviewed in ref. [5]). Though decades of genetic and
biochemical studies have given great insight into such mechan-
isms, much remains to be learned about the overall impact of cell
cycle transitions on intracellular physiology.
To date, cell cycle studies have focused primarily on the
regulation of DNA replication (S phase), chromosome segregation
(M phase), and cytokinesis. A few recent unbiased analyses of cell
cycle-associated changes in human mRNA abundance suggest that
other biological processes are also cell cycle-regulated [6,7].
Nevertheless, the full spectrum of cellular changes at the major cell
cycle transitions is still unknown. In particular, the mRNA changes
during the cell cycle in continuously growing cells are unlikely to
reflect the rapid changes in concentrations of critical proteins. A
2010 study by Olsen et al. analyzed both changes in protein
abundance and phosphorylation events in the human cell cycle,
focusing primarily on changes in mitosis [8]. In this current study,
we investigated protein abundance changes associated with S
phase relative to both G1 and G2 in highly synchronous HeLa
cells (human cervical epithelial carcinoma). In parallel, we have
catalogued changes in the proteome in response to inhibition of
ubiquitin-mediated degradation in synchronous cells. In addition
to finding some of the previously-described changes related to
DNA metabolism and mitosis, we also uncovered changes in many
proteins involved in alternative pre-mRNA splicing.
Materials and Methods
Cell Culture and Synchronization
HeLa cells were originally obtained from ATCC and were
cultured in three different media. ‘‘Light’’ cells were grown in
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depleted Dulbecco’s Modified Eagle Medium (DMEM; UCSF
Cell Culture Facility, CCFDA003-102I3C) reconstituted with
145 mg/L L-lysine (UCSF Cell Culture Facility, CCFGA002-
102M04) and 84 mg/L L-arginine (UCSF Cell Culture Facility,
CCFGA002-102J1X). ‘‘Medium’’ cells were grown in depleted
DMEM reconstituted with 798 mM L-lysine (4,4,5,5D4, DLM-
2640) and 398 mM L-arginine (13C6, CLM-2265). ‘‘Heavy’’ cells
were grown in depleted DMEM reconstituted with 798 mM L-
lysine (13C6;
15N2, CNLM-291) and 398 mM L-arginine (
13C6;
15N4, CNLM-539). All three media were supplemented to 10%
dialyzed fetal bovine serum (dFBS; Gibco, 26400-044) and 2 mM
L-glutamine (UCSF Cell Culture Facility, CCFGB002-101J04. All
modified isotopes were purchased from Cambridge Isotope
Laboratories, Inc. (Andover, MA). All HeLa cell cultures were
grown in the SILAC media for a minimum of 5 passages to ensure
that the amino acids had been fully incorporated. Labeling
efficiency was checked by examination of the tubulin and actin
proteins using LC-MS/MS (details of sample preparation and
analysis follow). T98G cells were originally obtained from ATCC
and were cultured in DMEM (Sigma Aldrich, D5648) supple-
mented with 10% FBS (Sigma Aldrich, F2442) and 2 mM L-
glutamine (Gibco, 25030-081). Cells were synchronized by serum
starvation for 72 hr and stimulated with a final concentration of
10% FBS [9].
To determine the protein changes between G1 and S phase,
simultaneously cultured biological replicates of HeLa cells were
subjected to double-thymidine synchronization as previously
described in ref. [7] with minor modifications. Ten hours after
release from the second thymidine block, the medium was
removed, and a mitotic shake-off was performed. Mitotic cells
were replated and collected at 3 hr (G1 sample) and 10 hr (S
sample). To capture proteins degraded after S phase onset, one
separately-labeled culture was treated with 20 mM MG132 (Sigma
Aldrich, C2211) for 2 hr prior to harvest (8 hrs after shakeoff). To
determine the protein changes between S and G2 phase,
simultaneously cultured biological replicates were harvested 3 hr
following release from the second thymidine treatment (S sample)
and 8 hr after release (G2 sample); one separately-labeled culture
received 20 mM MG132 2 hr prior to harvesting in G2. Cells were
harvested by trypsinization, collected by centrifugation, and cell
pellets were stored at 280uC prior to the preparation of cell
lysates. A small fraction of cells was fixed with ethanol, stained
with propidium iodide, and analyzed by flow cytometry to confirm
cell cycle phase.
Cell Lysis and Sample Processing
Frozen cell pellets were lysed in 50 mL high salt lysis buffer
(10 mM HEPES-KOH, pH 7.5 (H4034), 350 mM KCl (P9541),
3 mM MgCl2 (M8266), 1% Triton-X100 (T9284-100 mL), 1 mM
EDTA, pH 8.0 (Fisher Scientific, S311-500)) and incubated on ice
for 10 min. Lysis buffers were supplemented with 1 mM DTT
(D0632-5G), 0.1 mM AEBSF (Roche, 11585916001), 0.5 mM
NaOV4 (S6508-50G), 2 mM b-glycerolphosphate (G6376-25G),
2 mM NaF (201154-100G), 200 nM trichostatin A (T8552),
2.5 mM sodium butyrate (303410), and 1 mg/mL each of
aprotinin (A1153), leupeptin (L2884), and pepstatin A (P5318).
Unless otherwise indicated, all chemicals were purchased from
Sigma Aldrich. Lysates were cleared by centrifugation for 2 min at
4uC; the supernatant was transferred to a new tube and cleared by
centrifugation at full speed for 15 min at 4uC. Protein concentra-
tions were determined according to Bradford assay instructions
(Biorad, 500-0006). Samples were mixed 1:1:1 (70 mg each) and
subjected to SDS-PAGE on a 15% polyacrylamide gel. The gel
was stained with Coomassie blue (Amresco, M140-10G), and
sample lanes were continuously excised into 25 slices. The
following steps, including destaining, dehydration, reduction and
alkylation, and overnight in-gel trypsin digestion, were performed
following a standard protocol [10].
Desalting and LC-MS/MS
After digestion, the peptides were extracted using C18 ziptips
(Millipore, ZTC18S096), lyophilized, and resuspended in buffer A
(0.1% formic acid in H2O) prior to LC separation. MS analyses
were performed on an LTQ Orbitrap Velos (Thermo Scientific,
Bremen, Germany) coupled with a nanoLC-Ultra system
(Eksigent, Dublin, CA). Samples (5 mL) were loaded onto an
IntegraFrit column (C18, 75 mm 6 15 cm, 300 Å, 5 mm, New
Objective, MA). The peptides were eluted at a flow rate of 200 nl/
min with a linear gradient from 2% to 40% buffer B (0.1% formic
acid in acetonitrile) over the course of 110 min, followed by 80%
buffer B for another 10 min. At the end of the gradient, the
column was equilibrated for 10 min with 2% buffer B before
starting another LC/MS run. The mass spectrometer was
programmed to acquire spectra in a data-dependent and positive
ion mode at a spray voltage of 2.1 kV using the XCalibur software
(version 2.1, Thermo Scientific). Survey scans were performed in
the Orbitrap analyzer at a resolution of 15,000 over a mass range
between m/z 300-2,000. For each cycle, the top five most intense
ions were subjected to CID fragmentation in the LTQ with
normalized collision energy at 35% and activation Q 0.25;
dynamic exclusion was enabled. Selected ions were repeated once
and then excluded from further analysis for 45 sec. Unassigned
ions or those with a charge of 1+ were rejected. Maximum ion
accumulation times were 200 ms for each full MS scan and
100 ms for MS/MS scans. One microscan was acquired for each
MS and MS/MS scan. The mass spectrometry data from this
publication have been submitted to the Proteome Commons
Tranche (www.proteomecommons.org). The data from the G1 to
S dataset can be found using the following hash code:
ytUg3dJ7npt665b/ZRSADaIKbwhAbVLfVjOiV1qw0-
zUjr1f7rr+cJk6txiV+2CDE3cQEnKErNJ/mV6edECVH1y-
f4r70AAAAAAAAM5Q = = . The data from the S to G2 dataset
can be found using the following hash code:
Pfr5X84wSDM2MuckUXaXkFAqfoq2r94a-
KYgVm7NCTmz4L/pd5OpHEfoz3CxrMJfn-
Ze86hl8j2lJMDVZjSUkc1Du8hcQAAAAAAAAOuQ = = .
Database Search
The raw files were processed using the MaxQuant software suite
(version 1.2.0.34) [11]. The MS/MS spectra were used to
interrogate the UniProt human database (release date of
November 30, 2010. 20248 entries) using the Andromeda search
engine [12] with the precursor and fragment mass tolerances set to
6 ppm and 0.5 Da, respectively. Up to two missed cleavage sites
were allowed per peptide. Methionine oxidation and protein N-
terminal acetylation were chosen as variable modifications, and
cysteine carabamidomethlyation was set as a fixed modification for
database searching. Only peptides with a minimum length of 6
amino acids were considered for identification. Both peptide and
protein identifications were filtered to a maximum 1% false
discovery rate. Proteins identified from only a single peptide were
manually checked by direct visualization of the spectra and
quantified using the XCalibur software. Finally, the lists of
identified proteins were filtered to eliminate reverse hits and
known contaminants.
As a complement to MaxQuant the Proteome Discoverer
software (version 1.3, Thermo Scientific), configured with an in-
house Mascot server (v2.3, Matrix Science), was also used to
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search the same set of MS/MS data. A built-in workflow and
a ‘‘Quantification’’ module were used for protein identification
and quantitation. All the search parameters were the same as
the MaxQuant search, but were filtered at a false discovery rate
of 5% to quantify a similar number of proteins as had been
identified with MaxQuant. Both search strategies generated
overlapping protein lists (77%). Once results were gathered from
both programs, the results were combined. When proteins were
identified by both programs, the quantification calculated by the
MaxQuant software was reported. If the ratios were such that
one program defined a protein as changed whereas the second
program did not, the ratios were manually calculated through
integration of the peak areas using the XCalibur software.
Proteins were divided into subsets based on their SILAC ratios
using a 1.5-fold change as the cutoff threshold. That is, a ratio of
1.5 or higher was scored as an increase whereas a ratio of 0.666 or
less was scored as a decrease; ratios that fell between these values
were reported as no change. These ratios, as well as the log2
transformations, are reported in Tables S1 and S2.
Dataset Comparison and GO Term Analysis
The log2 transformed data from Whitfield et al. (2002) was
downloaded from www.cyclebase.org. Based on the calculated p-
value of periodicity, mRNA data were separated according to
mRNA peak time [13,14]. These lists were compared to our lists of
increased and decreased proteins, and p-values were calculated
using Fisher’s exact test; a p-value less than 0.01 was considered
significant. The same strategy was applied to comparisons to the
ubiquitome [15], a published ATM/ATR substrate list [16],
a published phosphoproteome [8], a Cyclin A/Cdk2 substrate list
[17], and a dataset that determined the subcellular localization of
proteins [18]. GO term analysis was performed using the DAVID
search engine [19,20]. Analysis was performed on the individual
lists, and the reported p-value was calculated using a modified
Fisher’s exact test. When GO terms overlapped, terms were
collapsed to the highest level (i.e., RNA splicing was collapsed into
RNA processing).
Immunoblot Validation
Samples were subjected to SDS-PAGE on a 12% polyacryl-
amide gel and transferred to PVDF (Thermo Scientific, 88518).
Blots were probed with the following antibodies: anti-Cyclin B1
(V152, Thermo Scientific, MA1-46103), anti-Cyclin A (C-19,
Santa Cruz Biotechnology, sc-596), anti-Cdc6 (D-1, Santa Cruz
Biotechnology, sc-13136), anti-Cdt1 [21], anti-Geminin (FL-209,
Santa Cruz Biotechnology, sc-13015), anti-SLBP [22], anti-a-
tubulin (DM1A, Sigma Aldrich, 9026), anti-RRM2 (Aviva Systems
Biology, ARP46031), anti-MARCKSL1 (Aviva Systems Biology,
ARP64193), anti-Palmdephin (Aviva Systems Biology,
ARP66420), anti-Prelamin A/C (N-18, Santa Cruz Biotechnology,
sc-6215), anti-Tropomodulin-3 [23], anti-MCM2 (46/BM28, BD
Pharmingen, 610700), anti-Rbmx/hnRNPG (Aviva Systems Bi-
ology, ARP61802), anti-hnRNPA1 (K350, Cell Signaling, 4296),
anti-hnRNPA3 (Y25, Santa Cruz Biotechnology, sc-133665), anti-
hnRNPD0 (T10, Santa Cruz Biotechnology, sc-22368), anti-
hnRNPL (Sigma Aldrich, SAB1405954), and anti-b-actin (N-21,
Santa Cruz Biotechnology, sc-130656). All HRP-conjugated
secondary antibodies were purchased from Jackson Immunor-
esearch (DaR 711-035-152, GaM 115-035-146, BaG 805-035-
180). Proteins were visualized following incubation with ECL
prime reagent (Amersham, RPN2232).
Results
Synchronous HeLa Cells Progressing through the G1/S
and S/G2 Transitions
We sought to investigate the proteome changes between G1 and
S phase and between S and G2 phase. Our goal was to achieve
very tight cell cycle synchrony while simultaneously avoiding
strong checkpoint effects that could be induced in chemically-
arrested cells. To facilitate accurate quantification of peptides by
mass spectrometry, we labeled cultures for more than 5 cell
divisions with three different stable isotope mixtures of lysine and
arginine (i.e. amino acid-coded mass tagging/AACT or stable
isotope labeling with amino acids in culture/SILAC) prior to
synchronization [24,25,26].
To obtain populations of isotope-labeled tightly-synchronous
cells progressing from G1 to S phase, we modified the Whitfield
et al. (2002) double-thymidine block and release protocol (Materi-
als and Methods) [7]. We released HeLa cells from the second
thymidine block (‘‘DT Block’’ = early S phase) to allow checkpoint
recovery and normal passage through the subsequent transitions
and allowed them to progress into mitosis without further chemical
perturbation. We collected mitotic cells using a ‘‘shake-off’’
method, a procedure that takes advantage of the tenuous
attachment of HeLa cells as they round up during mitosis. We
replated mitotic cells in fresh dishes, and 3 hrs after mitosis, the
cells were a relatively pure population of G1 cells; by 10 hrs after
mitosis they were in early-S phase (Figure 1A and 1B show a full
time course from cells grown in normal isotope medium). Note
that these cell cycle times reflect a moderate delay compared to
cells grown under standard conditions due to the requirement for
dialyzed fetal bovine serum for efficient metabolic labeling.
To facilitate the detection of proteins that may be rapidly
degraded in S phase we treated another culture of cells with the
proteasome inhibitor MG132 8 hrs after the mitotic shake-off (just
prior to the G1/S transition) and harvested the cells 2 hrs later in
early S phase. To quantify proteins that change between S phase
and G2 phase, we released cells into S phase from the double-
thymidine block rather than from a mitotic shake-off. These cells
progressed through S phase and entered G2 phase synchronously;
we harvested 3 hrs (S phase) and 8 hrs (G2 phase) after release
from the second thymidine block (Figure 1D and E show a full
time course from cells grown in normal isotope medium). We also
treated cells with MG132 6 hrs after release (just prior to the S/G2
transition) and harvested them 2 hrs later (G2 phase).
For the G1/S comparison, the G1 culture contained normal
isotopes (light), the early-S phase culture was metabolically labeled
with intermediate isotopes (medium), and the early-S phase culture
treated with MG132 at the G1/S transition had been cultured in
the heaviest isotopes (heavy). For the S/G2 comparison, mid-S
phase cells were cultured in the normal isotope medium (light), the
G2 cells were cultured in the intermediate isotope medium, and
the G2 cells that had been treated with MG132 at the S/G2
transition were labeled in heavy isotope medium. In this manner,
we generated synchronous metabolically-labeled cell populations
naturally passing from one phase to the next without the
potentially confounding issue of harvesting cells from a strong
checkpoint arrest.
We confirmed cell cycle position by immunoblotting whole cell
lysates for established cell cycle-regulated proteins. For example,
we confirmed that both the Cdc6 and geminin proteins, two
targets of the Anaphase Promoting Complex/Cyclosome (APC/C)
E3 ubiquitin ligase which is active from anaphase through late G1,
were substantially more abundant in the S phase lysates than in
the G1 lysates (Figure 1C, compare lanes 2 and 3 to lane 1)
Cell Cycle-Regulated Proteome: Splicing Proteins
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Figure 1. HeLa cell synchronization. A) Cells were synchronized by a modified double-thymidine block then released by re-plating and harvested
at the indicated time points; a late G1 phase culture was treated with MG132 two hrs prior to harvest in early S phase. Synchrony was determined by
flow cytometric analysis of DNA content. B) Immunoblot analysis of endogenous Cyclin A, Cdt1, SLBP, and tubulin proteins in whole cell lysates from
portions of the same cells used in A. C) Cells were metabolically labeled with stable isotopes and then synchronized in G1 (3 hrs after mitosis, normal/
‘‘light’’ isotopes) and early-S phase (10 hrs after mitosis, labeled with intermediate or ‘‘medium’’ isotopes) as in A and B. Cells labeled with the
heaviest isotopes were treated with MG132 two hrs prior to harvest in early S phase. Immunoblot analysis of endogenous Cdc6, Cdt1, and geminin in
whole cell lysates used for subsequent mass spectrometric tests. A non-specific band (NSB) serves as a loading control. D) Cells were synchronized by
double-thymidine block, released into S phase, and harvested at the indicated timepoints. Synchrony was determined by flow cytometric analysis of
DNA content. E) Immunoblot analysis of endogenous Cyclin B, SLBP and Cdt1 in whole cell lysates from portions of the same cells used in D. F) Cells
were metabolically labeled with stable isotopes and synchronized in S phase (light isotopes) or G2 phase (medium isotopes) as in D and E. A culture
labeled with heavy isotopes was treated with MG132 in late S phase for two hrs prior to harvest in G2. Immunoblot analysis of endogenous Cdt1 and
SLBP in whole cell lysates used for subsequent mass spectrometric analysis; b-actin serves as a loading control.
doi:10.1371/journal.pone.0058456.g001
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[27,28,29,30,31]. In contrast to Cdc6 and geminin, the Cdt1
protein is targeted for degradation at the onset of S phase by the
CRL4Cdt2 E3 ubiquitin ligase [32,33]. As expected, we detected
very little Cdt1 in the early-S phase cells compared to the G1 cells
(Figure 1C, compare lanes 1 and 2), but Cdt1 protein levels were
high in the S phase cells treated with MG132 (Figure 1C, compare
lanes 2 and 3). Moreover, we observed higher levels of Cdt1 in the
G2 samples compared to the mid-S phase samples as expected
because CRL4Cdt2 can only target Cdt1 during active DNA
replication (Figure 1F, compare lanes 1 and 2) [33,34,35].
Previously, we identified two proteins (SLBP and E2F1) that are
degraded at the end of S phase as a result of Cyclin A/Cdk1
activation. Their degradation is blocked by MG132 treatment
[36,37,38]. We detected not only the down-regulation of SLBP in
G2 phase but also its stabilization in cells treated with MG132
(Figure 1F). Finally we confirmed that MG132 did not prevent S
phase entry or exit as determined by flow cytometry and
immunoblot analysis of marker proteins Figures 1A and 1D).
We conclude therefore that these protocols generated synchronous
populations that display the expected differences in protein
abundance of known cell-cycle regulated proteins at the G1/S
and S/G2 transitions.
Protein Abundance Changes at the G1/S and S/G2
Transitions
Using these validated samples from synchronous cells, we
prepared whole cell lysates, combined the three lysates represent-
ing the G1/S comparison and the three lysates representing the S/
G2 comparison, and subjected them to SDS-PAGE. We divided
the gel into slices from which we generated tryptic peptides for
liquid chromatography separation and tandem mass spectrometry
(LC-MS/MS), as described in Materials and Methods. Using both
MaxQuant and Proteome Discoverer software, we analyzed
peptide spectra from a total of 50 gel slices. We identified
28,684 unique peptides corresponding to 2,842 unique proteins
(allowable false discovery rate of 5%). Spectra were of sufficient
quality to accurately quantify 2,410 of these proteins. A recent
very comprehensive analysis of the HeLa proteome detected a total
10,237 proteins from lysates of asynchronous cells indicating that
our analysis covers approximately 28% of the currently detectable
HeLa proteome [39]. Note that quantitation requires detection of
at least two isotopically labeled forms of the peptide, so any protein
that was clearly detectable in only one of the three cultures was
excluded from our analysis. Our dataset is also approximately 43%
as extensive as another recent proteome analysis of HeLa cells that
focused on changes during mitosis [8]. Interestingly, we detected
324 proteins not found in either previous report; these could reflect
proteins that are only abundant enough for detection at specific
cell cycle stages or could reflect random sampling differences
among the three studies (Figure 2A). Therefore, our proteome
analysis of the G1/S and S/G2 transitions complements and
extends other investigations of the HeLa cell proteome.
To focus specifically on proteins that change in abundance from
G1 to S phase, we compared the 1,611 quantifiable proteins (of
1,843 identified) from cells harvested in G1 to those from the
subsequent early-S phase time point. We chose a 1.5-fold change
in protein abundance as the threshold to score a protein as
increased or decreased; these changes were calculated using the
mean of all peptides from the same protein. Between these two cell
cycle phases, two-thirds (67.3%) of the proteins neither increased
nor decreased in abundance, whereas 32.7% either accumulated
or decreased between G1 and S phase (Figure 2B and C). We
quantified 1,640 proteins from the S/G2 comparison (of 1,913
identified). In contrast to the G1/S comparison, a higher pro-
portion (84.7%) of these proteins did not change by more than 1.5-
fold from S to G2 phase. Of the total quantifiable proteins, 15.3%
either increased or decreased in their abundance (Figure 2B and
D). These protein lists are provided in Tables S1 and S2, and the
individual peptide lists are provided in Table S6.
The pharmacological inhibitor MG132 blocks the activity of the
26S proteasome, leading to the accumulation of proteins targeted
for polyubiquitination [40,41]. Since many cell cycle transitions
are driven by ubiquitin-mediated protein degradation, we
reasoned that we could identify some of these proteins based on
altered abundance in the presence of MG132. It is important to
note that MG132 was added close to the cell cycle transition under
investigation. Overall, ,1% of S phase proteins and 8% of G2
proteins were induced by MG132 treatment for 2 hrs compared to
untreated early-S phase and G2 cells, respectively (Figure 2B, E
and F, and Tables S3.1 and S4.1). We also detected proteins that
were induced by treatment with MG132 that had not shown
changes between cell cycle phases. These proteins could have short
half-lives and be subject to continuous ubiquitin-mediated
degradation at many or all cell cycle phases. Interestingly, more
proteins were down-regulated after MG132 treatment than were
induced - 13% of S phase and 10% of G2 proteins (Figure 2B, and
Tables S3.2 and S4.2). A similar phenomenon has been reported
previously; one study reported that 15% of proteins were down-
regulated at least 2-fold after treating asynchronous cells with
MG132 for 4 hrs [42]. The complete list of protein changes in
response to MG132 treatment for both datasets is provided as
Tables S3 and S4.
Some of the protein changes observed from one cell cycle phase
to the next, such as cyclin B induction in G2, are well known. All
the known cell cycle-regulated proteins that we detected changed
as expected, although several relatively low abundance proteins
were not detected. For example, the average abundance of
peptides derived from ribonucleoside-diphosphate reductase sub-
unit M2 (RRM2) increased 4.8-fold in S phase. This protein is
regulated both at the transcriptional level, as a target of E2F4
repression, and at the protein level, as a target of the APC/C
ubiquitin ligase [43,44,45].
Our data also predicted changes in protein abundance that have
not been previously identified. We selected several of these proteins
for immunoblot validation on the original lysates of synchronized
HeLa cells. Most of the proteins (17 out of 28) we selected for this
validation showed changes in abundance that were consistent with
the mass spectrometry quantification. For example, MARCKS-
related protein (MARCKSL1) and palmdelphin (Palmd) increased
in S phase compared to G1 phase by 2.9-fold and 2.0-fold,
respectively, and we observed increases in band intensities for these
proteins by immunoblotting (Figure 3A, compare lanes 1 and 2).
Furthermore, mass spectrometry indicated that prelamin A/C
protein levels decreased 4.7-fold in S phase compared to G1, and
immunoblot analysis supported this finding (Figure 3A). As an
example of a protein that does not change between G1 and S phase,
we found that tropomodulin-3 (Tmod3) protein levels did not
change significantly, in agreement with the mass spectrometry
analysis. The total number of proteins that changed (increased or
decreased) between S and G2 was smaller than the number of
proteins that changed between G1 and S phase. We selected several
proteins for validation by immunoblot analysis as above. For
example, the average peptide abundance derived from prelamin A/
C and cyclin B1 increased in G2 phase compared to mid-S phase by
1.7-fold and 2.1-fold, respectively; we observed changes in band
intensities consistent with these mass spectrometry results (Figure 3B,
compare lanes 1 and 2).
Cell Cycle-Regulated Proteome: Splicing Proteins
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Frequent Discordance of mRNA and Protein Abundance
Changes in protein abundance can often be explained by
corresponding fluctuations in mRNA abundance. A landmark
study by Whitfield et al. (2002) catalogued changes in mRNA
expression through multiple synchronous cell cycles in HeLa cells
[7]. The primary data from this extensive analysis is readily
available for interrogation (cyclebase.org), and we sought to
determine the relationship between mRNA expression in the
Whitfield study with the protein changes we detected in this study.
We divided the mRNA data into groups based on peak cell cycle
phase of abundance [13,14]. We then determined which of the
proteins that changed from one cell cycle phase to the next in our
study were also the products mRNAs whose abundance changed
in the same way. Somewhat surprisingly, there was no significant
overlap between the mRNAs that peak in S phase and the detected
proteins that increased in S phase; likewise, proteins that decreased
in S phase were unlikely to be the products of mRNAs that
decreased in S phase (Figure 4A, first two bars). This poor
correlation also existed when we compared proteins that increased
in S phase to mRNAs that peaked in G1. As pointed out by
Whitfield et al., there were fewer changes in mRNA levels
between G1 and S phase than there were between S and M
phase; only 19.5% of transcripts peak in S phase whereas 45%
peak in G2/M [7].
In contrast, proteins that increased in G2 were somewhat more
likely to be the products of mRNAs that also increased in G2
(Figure 4A, third bar). For example, the prelamin A/C mRNA
peaks in G2/M, and the protein also modestly increased in our G2
samples compared to S phase (Figure 3B, compare lanes 1 and 2).
In contrast, proteins that decreased in G2 were not well-predicted
by mRNAs that also decreased in G2 (Figure 4A, fourth bar).
Furthermore, when we compared the proteins that did not change
in either of our datasets to the mRNAs that are constitutively
expressed throughout the cell cycle, more than 60% of the genes/
proteins were in agreement (Figure S1, first two bars). When the
set of constitutive proteins were compared to the mRNAs that
fluctuate, this overlap was much smaller, though still statistically
significant (Figure S1). Thus, some of the proteins whose
Figure 2. Cell cycle-regulated proteins from G1 to S and S to G2 detected by mass spectrometry. A) Comparison of the total number of
proteins detected in this study (2,842 proteins) to two other studies of the HeLa cell proteome: Nagaraj et al., 2011 (10,237 proteins) [39] and Olsen
et al., 2010 (6,695 proteins) [8]. B) Quantified proteins from this study were divided into lists based on their fold and direction of change; the total
protein count for each list is plotted. ‘‘NC’’ denotes proteins that did not change. ‘‘NC MG,’’ ‘‘Inc MG,’’ and ‘‘Dec MG’’ denote proteins that either did
not change, increased, or decreased in response to MG132 treatment, respectively. C) All quantifiable proteins in the G1 to S dataset plotted by their
log2 transformed isotope ratios (medium S phase/light G1 phase). Dotted lines denote the 1.5-fold change threshold. D) All quantifiable proteins
identified in the S to G2 dataset plotted by their log2 transformed isotope ratios (medium G2 phase/light S phase); dotted lines denote the 1.5-fold
change threshold. E) Proteins identified in early-S phase cells compared to early-S phase cells treated with MG132 plotted by their log2 transformed
isotope ratios (heavy S phase plus MG132/medium S phase minus MG132). Dotted lines denote the 1.5-fold change threshold. F) Proteins identified in
G2 phase cells compared to G2 phase cells treated with MG132 plotted by their log2 transformed isotope ratios (heavy G2 plus MG132/medium G2
phase minus MG132). Dotted lines denote the 1.5-fold change threshold.
doi:10.1371/journal.pone.0058456.g002
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abundance did not change by mass spectrometry analysis are the
products of mRNAs that do change; these proteins may be long-
lived and thus not fully reflective of corresponding mRNA
changes.
Since mRNA abundance could not fully account for the protein
changes we observed, we considered the possibility that the
changes in protein abundance were correlated with ubiquitination
and thus, regulated protein degradation. We compared our lists of
proteins that change from G1 to S or from S to G2 to a recently-
published list of ubiquitinated proteins identified in asynchronous-
ly growing HCT116 (human colon carcinoma) cells [15].
Strikingly, a high proportion of the proteins that either increased
(56.7%) or decreased (62.6%) between G1 and S also appeared in
the list of 4,462 ubiquitinated proteins (Figure 4B, first two bars).
Moreover, proteins whose abundance was affected by MG132
treatment in S phase (either increased or decreased) were also
highly represented in the reported list of total ubiquitinated
proteins. In contrast, proteins that changed from S to G2 were not
as enriched in the ‘‘ubiquitome,’’ regardless of MG132 treatment
with the exception of proteins that increased from S phase to G2
(Figure 4B).
Both nuclear and cytoplasmic proteins were present in all of our
datasets, and we detected no differences in nuclear-cytoplasmic
localization among proteins that changed from one cell cycle
phase to the next (Figures S2A and S2B). A strikingly large
proportion of proteins whose abundance changed from G1 to S or
from S to G2 have been detected as phosphoproteins, consistent
with the notion that many protein abundance changes are
controlled by phosphorylation (Figure 4C). This enrichment was
true both for proteins that changed from G1 to S and for those
that changed from S to G2.
Since the cyclin-dependent kinases (Cdks) govern many cell
cycle transitions, we compared our sets of regulated proteins with
a list of candidate Cdk substrates [17]. Many proteins that
increased (6 of 31) or decreased (28 of 496) in S phase appear on
this list of Cdk substrates (Figure 4D, first two bars). Moreover,
a statistically significant number of proteins that increased in G2
phase are also putative Cdk substrates (Figure 4D, fifth bar). A
significant number of proteins that changed with MG132
treatment at the S/G2 transition are also putative Cdk substrates
(Figure 4D, last two bars). In contrast, proteins that changed in
response to MG132 treatment at the G1/S transition were not
enriched for putative Cdk substrates (Figure 4D, third and fourth
bars).
Like Cdks, the ATR kinase is active during S phase [46]. ATR
activity is also stimulated by DNA damage, and this property was
used to identify candidate ATR substrates. Putative ATR kinase
substrate lists were developed by Stokes et al. (2007) from
phosphopeptides detected following UV irradiation, an activator
of ATR [16]. A subset of our regulated proteins also appeared in
these lists of potential ATR substrates (Figure 4E). The majority of
proteins that change with MG132 treatment, (both lists), were not
ATR substrates, but proteins that decreased with MG132
treatment at the S/G2 transition were significantly enriched in
ATR substrates (Figure 4E). Taken together, these comparisons
are consistent with the prevailing model that many changes in
protein abundance between G1 and S phase and between S and
G2 phase are associated with both protein ubiquitination and
protein phosphorylation, but this analysis also underscores the idea
that only some changes, particularly as cells progress from G1 to S
phase in continuously growing cells, are due solely to mRNA
fluctuations.
Unanticipated Cell Cycle-regulated Proteins Include
Alternative pre-mRNA Splicing Factors
To determine which biological processes might be cell cycle-
regulated, we analyzed the Gene Ontology (GO) enrichment of
each of our lists. As expected, ‘‘cell cycle’’ was enriched in our sets
of cell cycle-regulated proteins (increase in G2). The three most
highly-enriched terms for each list are shown in Table 1, and the
full list is provided in Table S5. Proteins involved in cell
morphogenesis increased from G1 to S phase, whereas proteins
assigned to the GO term ‘‘protein folding’’ decreased (Table 1)
from S to G2 phase. Surprisingly, proteins involved in RNA
processing and ribonucleoprotein complex biogenesis were signif-
icantly represented in the set of proteins that decreased from G1 to
Figure 3. Validation of selected cell cycle-regulated protein predicted by mass spectrometry. The same cell lysates analyzed by mass
spectrometry were subjected to immunoblot analysis for the indicated endogenous proteins in the A) G1 to S lysates or B) S to G2 lysates. Reported
fold change ratios from mass spectrometry are listed to the right.
doi:10.1371/journal.pone.0058456.g003
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S phase and the set that increased from S to G2 phase. (The
proteins that decreased from G1 to S phase are not necessarily the
same proteins that were increased in the S to G2 dataset.) Both sets
of MG132-sensitive proteins were also enriched for RNA
processing and ribonucleoprotein complex biogenesis proteins
(Table 2).
The striking enrichment of pre-mRNA processing proteins in
the collection of proteins that were down-regulated in S phase
prompted us to analyze those proteins more directly. In particular,
the enriched GO terms included nuclear pre-mRNA splicing, and
more specifically, alternative splicing (Figure 5A). Of the 244
known splicing factors, we detected 72 core proteins and 65 non-
core proteins (Table S7) [47]. Overall, we detected 31.9% of the
core spliceosome proteins, of which 46.7% decreased in S phase
(Figure 5B, first bar). Of note, proteins in the U2 complex
decreased, suggesting that a specific part of the core machinery
Figure 4. Discordance between mRNA and protein abundance. A) Individual lists of proteins that changed by at least 1.5-fold were compared
to the mRNA data for those same proteins in synchronized HeLa cells from Whitfield et al. 2002 [7]. The percentage of proteins whose corresponding
mRNA also changed is graphed for both S phase and G2 phase. ** p,0.001. B-E) Individual lists of proteins that changed by at least 1.5-fold were
compared to proteins predicted to be B) ubiquitinated in asynchronous HCT116 cells [15], C) phosphorylated in HeLa cells [8], D) substrates of Cyclin
A/Cdk2 [17], and E) substrates of the ATR kinase [16]. The percentage of each list that overlaps with the published dataset is plotted. * p,0.01; **
p,0.001.
doi:10.1371/journal.pone.0058456.g004
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may be regulated during S phase. Additionally, we detected 58.7%
of the non-core spliceosome machinery, and 62.3% of these
subunits decreased in S phase (Figure 5B, second bar). Strikingly,
we quantified almost all (95.7%) of the known heterogeneous
nuclear ribonucleoproteins (hnRNPs), and 72.7% of these proteins
decrease in S phase (Figure 5B, third bar). These proteins are
important in determining exon inclusion, suggesting that alterna-
tive splicing is particularly affected during S phase [48,49,50,51].
We probed several of the alternative splicing factors by
immunoblotting to determine if the changes observed by mass
spectrometry were valid. As shown in Figure 5C, several hnRNPs
decreased between G1 and S phase, such as hnRNPG, hnRNPA1,
and hnRNPL (compare lanes 1 and 2). For two other proteins,
hnRNPA3 and hnRNPD0, we detected multiple isoforms that
clearly changed between G1 and S phase. Some isoforms
decreased in abundance but new isoforms accumulated in the S
phase samples (Figure 5C, compare lane 1 with lanes 2 and 3). Of
note, the hnRNPA3 protein has been reported to be heavily
phosphorylated, raising the possibility that the decrease observed
by mass spectrometry was due to cell cycle regulated post-
translational modifications [52,53,54,55,56,57,58,59]. Indeed,
a number of hnRNPs, including hnRNPD0, were identified as
Cyclin A/Cdk2 substrates [17]. Moreover, we confirmed S phase
downregulation of hnRNPG in biological replicates of synchro-
nized HeLa cells (Figure S3A) and S phase downregulation of
hnRNPA3 in another line, T98G (Figure S3B). Additionally, none
of the splicing proteins that decreased in S phase were the products
of mRNAs that also decreased in S phase (for example, hnRNPG
is shown in Figure 5D, others in Figure S4), suggesting that their
regulation must be posttranscriptional.
Discussion
Previous unbiased analyses of the human transcriptome and
proteome have generated an appreciation for the interconnected-
ness of different biochemical pathways. Inspired by such findings,
we considered it likely that the human cell cycle includes changes
not only in the well-studied processes of chromosome replication,
mitosis, and cell division, but also changes in other cellular
processes. This hypothesis was supported by our discovery that
proteins involved in alternative pre-mRNA splicing are down-
regulated in S phase. The reason for this apparent systemic
regulation of pre-mRNA splicing has yet to be elucidated, but
could reflect a need to rapidly alter the isoforms of a cohort of
proteins from one cell cycle phase to the next. The depth of our
proteome coverage likely reflects changes in the most abundant
and readily detectable proteins; thus these fluctuations indicate
novel biological pathways and processes that are cell cycle-
regulated even when the rarest proteins were not quantified.
Alternative splicing, particularly the production of different
isoforms of specific mRNAs at different times in the same cell, is
determined by cis elements (splicing enhancers and splicing
silencers) and the relative concentrations of the trans factors,
splicing activators and repressors (reviewed in ref. [60]). Changes
in the relative concentrations of these regulatory proteins are
responsible for most of the changes observed in alternative
Table 1. Top three significant GO terms enriched in individual lists of cell cycle-regulated proteins.
Increase in S phase
GO Term p-value Protein Count
Regulation of cell morphogenesis 0.001 4
Negative regulation of cellular component organization 0.024 3
Negative regulation of cell projection organization 0.047 2
Decrease in S phase
GO Term p-value Protein Count
RNA processing 3.96e234 83
Ribonucleoprotein complex biogenesis 1.98e220 38
Translational elongation 2.46e218 28
Increase in G2 phase
GO Term p-value Protein Count
RNA processing 2.25e205 16
Cell cycle 0.001 16
Cellular protein localization 0.002 11
Decrease in G2 phase
GO Term p-value Protein Count
Protein folding 0.007 6
Macromolecular complex assembly 0.015 11
Positive regulation of anti-apoptosis 0.018 3
doi:10.1371/journal.pone.0058456.t001
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splicing. Thus, relatively small changes in the concentrations of
these common splicing regulatory proteins, particularly the
hnRNPs and SR proteins, can result in changes in a number of
coordinately regulated alternative splicing events [61,62,63,64].
This study extends and complements the cell cycle proteome
analysis by Olsen et al. [8]. Our cells were not only very tightly
synchronized in early S phase by the double-thymidine and
mitotic shakeoff protocol, but importantly, we collected cells as
they progressed synchronously through the cell cycle after release
from the block. This protocol is distinct from other popular
synchronization methods in which cells were harvested while
chemically arrested with replication or mitotic inhibitors or were
harvested very shortly after release from such inhibitors. Likely
due to these differences, a comparison of proteins that change
from G1 to S or from S to G2 in our dataset to those reported by
Olsen et al. (using a single block and release or nocodazole block
and release) showed little overlap. Nevertheless, the alternative
splicing factors we detected were also reported in the Olsen
dataset, although the amplitudes of those changes were less than
those we measured. These differences may be due to technical
variations in culture conditions (for example, adherent vs.
suspension cultures) or to differences in the degree of cell cycle
synchrony. One area of close agreement between the two studies,
however, is the conclusion that only a subset of cell cycle-regulated
changes in protein abundance can be accounted for by changes in
mRNA abundance.
Although many protein changes detected in this study did not
match corresponding changes in mRNA levels, we noted a clear
difference between the degree of concordance of the mRNA
changes and protein changes between the two G1-to-S and S-to-
G2 datasets. Proteins that increased from S to G2 were more likely
to be the products of mRNAs that showed similar cell cycle-
dependent changes, though these mRNA changes were only able
to predict ,10% of these G2-inducible proteins (Figure 4A). This
relationship is consistent with the finding that 45% of the cell cycle
regulated mRNAs peak in G2/M [7]. Strikingly, more than half of
the proteins that changed – either increased or decreased – from
G1 to S phase are among those reported to be polyubiquitinated,
but this enrichment was much less or non-significant for proteins
that changed from S to G2 (Figure 4B). Taken together, our
analysis is consistent with the notion that protein changes from S
to G2 are somewhat reflective of changes in mRNA levels, but
proteins that change from G1 to S are reflective of ubiquitin-
mediated protein degradation and phosphorylation.
Given the importance of ubiquitin-mediated protein degrada-
tion in cell cycle transitions, and that a number of cell cycle
regulators change concentrations rapidly without concomitant
changes in mRNA concentrations, we included analysis of cells
treated with the proteasome inhibitor MG132. A relatively small
number of proteins that increase after MG132 treatment at the
G1/S transition were detected, whereas a larger number of
MG132-inducible proteins were detected in cells treated at the S/
G2 transition (Figure 2B and Tables S3.1 and S4.1). Interestingly,
at least as many proteins were MG132-repressible as were MG132-
inducible in both experiments (Figure 2B and Tables S3.2 and
S4.2). Given the mechanism of action of MG132 as a competitive
inhibitor of the 26S proteasome, we interpret these changes as
a reflection of indirect cellular responses to the accumulation of
polyubiquitinated proteins or the prevention of degradation of
specific proteins. Some of the MG132-repressible proteins may
themselves be targets for negative regulation by MG132-inducible
repressors. Those targets of negative regulation would therefore be
indirectly repressed by MG132. In addition, the loss of proteasome
function may trigger a cellular stress response that is reflected in
the proteome as down-regulation of a cohort of proteins. Of note,
proteasome inhibitors are a chemotherapeutic strategy for anti-
cancer treatment [65,66], and prolonged treatment of HeLa cells
with MG132 (e.g. 24 hrs) results in apoptosis [67]. Our report here
of proteins whose levels change in response to MG132 at two
specific cell cycle phases sheds additional light on the biological
responses to such strategies.
A major challenge in this type of study is the detection of
relatively low abundance proteins, many of which are critical
regulators of cellular processes. Many of the previously defined cell
cycle regulated proteins, often regulated by proteolysis, were not
detected. These include SLBP, a critical regulator of histone
mRNA metabolism, the E2F1-3 transcription factors, which are
essential for the transcription of S phase genes, and many proteins
needed for the formation of the pre-replication complex (Orc
subunits, Cdc6, Cdt1, etc.). Detection of these low abundance
proteins will require further advances in proteomics technology,
perhaps through some method that removes the most abundant
proteins, similar to how ‘‘ribo-minus’’ technology removes the
most abundant RNAs to allow the detection of very low
abundance RNAs by high-throughput sequencing.
Studies such as the one presented here add to our general
knowledge of the global changes that can occur during the cell
cycle. We expect that the combination of this analysis with other
studies focused on mitosis, the phosphoproteome, the transcrip-
tome, the ubiquitome, cell cycle changes in model organisms, etc.
Table 2. Top three significant GO terms enriched in the
individual lists of MG132-sensitive proteins.
Increase in S phase following MG132 treatment
GO Term p-value Protein Count
Signal complex assembly 0.009 2
Cell migration 0.011 3
Cellular macromolecular complex assembly 0.014 3
Decrease in S phase following MG132 treatment
GO Term p-value Protein Count
Ribonucleoprotein complex biogenesis 2.59e210 17
Ribosome biogenesis 1.57e207 12
RNA processing 3.09e207 23
Increase in G2 phase following MG132 treatment
GO Term p-value Protein Count
Translational elongation 5.44e2130 68
Ribosome biogenesis 1.01e214 16
Ribonucleoprotein complex biogenesis 2.13e213 17
Decrease in G2 phase following MG132 treatment
GO Term p-value Protein Count
Protein transport 1.45e205 20
Protein localization 3.30e205 21
mRNA processing 7.03e205 12
doi:10.1371/journal.pone.0058456.t002
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will facilitate a complete systems-level understanding of the cell
cycle.
Supporting Information
Figure S1 Proteins that did not change in either the G1
to S or the S to G2 dataset were compared to mRNAs that
were ubiquitously expressed or peaked at the indicated
cell cycle phases [7]. * p,0.01; ** p,0.001.
(PDF)
Figure S2 Individual lists were compared to the Bois-
vert et al. (2012) data, which examined the subcellular
location of proteins [18]. ‘‘Ubiquitous’’ denotes proteins that
were found in both the nuclear and cytoplasmic fractions, whereas
‘‘Nuclear’’ or ‘‘Cytoplasmic’’ proteins were found only in that
compartment. Data from the A) G1 to S dataset and B) the S to
G2 dataset are represented as the percentage of the individual list
that overlaps with the published dataset. * p,0.01; ** p,0.001.
(PDF)
Figure S3 A) HeLa cells were synchronized as in Figure 1A and
the endogenous levels of hnRNPG were examined. A non-specific
band (NSB) was used as a loading control. B) T98G cells were
synchronized in quiescence by serum starvation and stimulated to
re-enter the cell cycle with 10% FBS; S phase entry begins at
20 hr. post-serum addition [9]. Lysates were analyzed for levels of
endogenous hnRNPA3; a-tubulin serves as a loading control.
(PDF)
Figure S4 Individual mRNA abundance data were
extracted from the Whitfield et al. (2002) dataset [7];
expression data from 3 double-thymidine block and
release experiments are shown as a function of cell cycle
phase for A) hnRNPA1, B) hnRNPA2/B1, C) hnRNPD,
and D) hnRNPL.
Figure 5. pre-mRNA alternative splicing factors are enriched among proteins that decrease from G1 to S phase. A) The GO term
analysis tree of a branch of RNA metabolism is shaded to indicate decreasing p-values for the enrichment in the protein datasets of this study. B)
Spliceosome proteins were designated as either core or non-core proteins; hnRNPs represent a subset of the non-core spliceosome proteins [47]. The
total percentage of the category of splicing proteins is plotted. The portion of the bars shaded blue represents the percentage that decreased
between G1 phase and S phase, and the portion shaded green represents the fraction that did not change between G1 and S phase. The full list of
splicing proteins quantified is provided in Table S7. C) Whole cell lysates from synchronized cultures (Figure 1C) were analyzed for the indicated
endogenous hnRNP proteins; the fold change ratios from mass spectrometry are listed to the right. b-actin serves as a loading control. D) mRNA
abundance for the hnRNPG gene was extracted from the Whitfield et al. (2002) dataset [7]; expression data from 3 double-thymidine block and
release experiments are shown as a function of cell cycle phase.
doi:10.1371/journal.pone.0058456.g005
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(PDF)
Table S1 Combined protein IDs and quantitation ratios
for the G1 to S dataset.
(XLS)
Table S2 Combined protein IDs and quantitation ratios
for the S to G2 dataset.
(XLS)
Table S3 Protein changes induced by MG132 added at
the G1/S phase transition and harvested 2 hrs later in
early S phase.
(XLS)
Table S4 Protein changes induced by MG132 treatment
at the S/G2 transition and harvested 2 hrs later in G2
phase.
(XLS)
Table S5 Full GO term analysis of individual protein
lists.
(XLS)
Table S6 Peptide IDs and quantitation ratios for both
datasets.
(XLS)
Table S7 Splicing proteins down-regulated in S phase.
(XLS)
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